56012-38-5

Usage

Uses

Used in Fragrance Industry:
(2-Methyl-1,3-thiazol-5-yl)Methanol is used as a fragrance ingredient for its pleasant floral and fruity odor, contributing to the scent profiles of perfumes, soaps, and other personal care products.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, (2-Methyl-1,3-thiazol-5-yl)Methanol serves as a building block in the synthesis of various pharmaceutical compounds, leveraging its chemical structure to create new therapeutic agents.
Used in Research and Development:
(2-Methyl-1,3-thiazol-5-yl)Methanol is utilized in research for its potential anti-inflammatory and antifungal properties, indicating its possible applications in the development of new treatments for inflammatory and fungal conditions.
It is crucial to handle (2-Methyl-1,3-thiazol-5-yl)Methanol with care due to its potential to cause irritation to the skin, eyes, and respiratory tract, emphasizing the need for proper safety measures during its use in various applications.

Upstream product

• 79836-78-5 ethyl 2-methylthiazole-5-carboxylate 
• 50-00-0 formaldehyd 
• 3581-87-1 2-methylthiazole 
• 53233-90-2 methyl 2-methylthiazole-5-carboxylate 
• 1003-60-7 2-methylthiazole-4-carboxyaldehyde 
• 40004-69-1 2-methyl-1,3-thiazole-5-carboxylic acid 

Downstream Products

• 63140-11-4 2-methyl-5-thiazolylmethyl chloride 
• 1003-60-7 2-methylthiazole-4-carboxyaldehyde 
• 60628-44-6 2-methyl-5-[(N,N-dimethylcarbamoyloxy)-methyl]-thiazole hydrochloride 
• 60628-45-7 2-methyl-5-(N-phenylcarbamoyloxymethyl)-thiazole hydrochloride 
• 60628-43-5 2-methyl-5-(N-methylcarbamoyloxymethyl)-thiazole 
• 1569070-23-0 C₂₈H₂₄FN₃O₄S*ClH 
• 63139-97-9 (2-methyl-1,3-thiazol-5-yl)methanamine 
• 40004-69-1 2-methyl-1,3-thiazole-5-carboxylic acid 

Relevant academic research and scientific papers

BICYCLIC HETEROAROMATIC AMIDE COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

BTK Inhibitors and uses thereof

The invention discloses a bruton's tyrosine kinase (BTK) inhibitor and use thereof. Specifically, the invention provides heteroaromatic compounds or stereoisomers, geometrical isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions containing the heteroaromatic compounds; the invention also discloses use of the heteroaromatic compounds or the pharmaceutical compositions containing the heteroaromatic compounds in preparation of medicines; the medicines can be used for treating autoimmune diseases, inflammatory diseases or proliferative diseases.

Low-temperature catalytic hydrogenation of bio-based furfural and relevant aldehydes using cesium carbonate and hydrosiloxane

Selective hydrogenation of unsaturated compounds is mainly carried out by using high-pressure hydrogen in the presence of a precious or transition metal catalyst. Here, we describe a benign approach to efficiently catalyze the hydrogenation of furfural (FUR) to furfuryl alcohol (FFA) over commercially available cesium carbonate using nontoxic and cheap polymethylhydrosiloxane (PMHS) as hydrogen source. Good to excellent FFA yields (≥90%) could be obtained at 25-80 °C by appropriate control of the catalyst dosage, reaction time, and the hydride amount. FUR-to-FFA hydrogenation was clarified to follow a pseudo-first order kinetics with low apparent activation energy of 20.6 kJ mol-1. Mechanistic insights manifested that PMHS was redistributed to H3SiMe, which acted as the active silane for the hydrogenation reactions. Importantly, this catalytic system was able to selectively reduce a wide range of aromatic aldehydes to the corresponding alcohols in good yields of 81-99% at 25-80 °C in 2-6 h.

IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS

Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis. The process of preparation of the compounds of Formula (I), (II), and (III), their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, along with a pharmaceutical composition comprising a compound of Formula (I), Formula (II), Formula (III), or a pharmaceutically acceptable salt thereof have also been described.

HEPATITIS B CORE PROTEIN MODULATORS

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound of formula:

QUINAZOLINE DERIVATIVE

Provided are a quinazoline derivative, a pharmaceutical composition containing the same, a method for preparation of said derivative, and an application of same as an anti-cancer drug.

PROTEIN KINASE INHIBITORS

The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.

PROTEIN KINASE INHIBITORS

The present invention relates to a novel family of inhibitors o f protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families

PROTEIN KINASE INHIBITORS

The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families, more particularly Btk, having the general formula (1): A-Y-E-W-Z (1.)

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein X1, X2, W, R1 to R5, L and m have the meaning according to the claims, are glucosidase inhibitors, and can be employed, inter alia, for the treatment of Alzheimer's disease.